Abstract: Described is a method for treating and/or preventing vestibulodynia by administering a therapeutically effective amount of a composition to a subject in need thereof The composition can include at least one non-ionic cellulose ether being hydroxypropylmethylcellulose (HPMC), one or more pH regulating agent(s) that includes a lactate and/or a citrate buffer , and water. The composition can have a pH from 3 to 5, a viscosity from 35000 to 100 000 mPas, said viscosity being measured at 20° C. according to European Pharmacopeia 7.0, 2.210, and being free from any additional active pharmaceutical agent, wherein the composition includes from 1 wt % to 5 wt % of said non-ionic cellulose ether based on the total weight of the composition.

Abstract: The present document is directed to a pharmaceutical composition comprising: at least one non-ionic cellulose ether, one or more pH regulating agent(s), and an aqueous solvent, said composition having a pH from 3 to 5, a viscosity from 35000 to about 100 000 mPas and being free from any additional active pharmaceutical agent for use in the treatment and/or prevention of vestibulodynia.

Abstract: Described is a urogenital cleansing composition that includes a non-ionic cellulose ether, an aqueous solvent, a triglyceride oil and a pH-regulating agent, wherein the urogenital cleansing composition does not contain any additional emulsifier and have a pH within the range of from 3 to 4 and wherein the pH-regulating agent is a lactate buffer.

Abstract: Described is a urogenital cleansing composition that includes a non-ionic cellulose ether, an aqueous solvent, a triglyceride oil and a pH-regulating agent, wherein the urogenital cleansing composition does not contain any additional emulsifier and have a pH within the range of from 3 to 4 and wherein the pH-regulating agent is a lactate buffer.